When cancer metastasizes to bone, considerable pain and deregulated bone remodelling
occurs, greatly diminishing the possibility of cure. Metastasizing tumour cells mobilize and …

Since the discovery that deletion of the NF-κB subunits p50 and p52 causes osteopetrosis in
mice, there has been considerable interest in the role of NF-κB signaling in bone. NF-κB …

Zoledronic acid (ZA) is one of the most important and effective class of anti-resorptive drug
available among bisphosphonate (BP), which could effectively reduce the risk of skeletal …

Bisphosphonates, especially nitrogen-containing bisphosphonates (N-BPs), are widely used
to preserve and improve bone health in patients with cancer because they inhibit osteoclast …

Integrins on both tumor cells and the supporting host stromal cells in bone (osteoclasts, new
blood vessels, inflammatory cells, platelets and bone marrow stromal cells) play key roles in …

Purpose: Osteonecrosis of the jaw (ONJ) is a growing concern in patients who receive
bisphosphonates that target osteoclasts. As osteoclasts play multifunctional roles in the …

Cancer becomes the leading cause of deaths worldwide, including breast cancer, prostate
cancer and lung cancer that preferentially metastasize to bone and bone marrow …

Blockade of osteoclast (OC) activity efficiently decreases tumor burden as well as associated
bone erosion in immune-compromised animals bearing human osteolytic cancers. In this …

INTRODUCTION: Zoledronic acid (ZOL), a nitrogen-containing bisphosphonate, is a potent
inhibitor of farnesyl-pyrophosphate synthase with poor in vitro cytotoxic activity as a result of …

Introduction Bone metastasis is the most common complication of advanced breast cancer.
The associated cancer-induced bone disease is treated with bone-sparing agents like …